EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study

Jianping Wang, Jian Zhang, Jie Gao, Mengmeng Zhao, Zhenkai Ma

Advances in Clinical and Experimental Medicine · 2023

DOI: 10.17219/acem/170265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Jianping Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, People's Hospital of Yangzhong, China. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsPaclitaxelAntibodies, Monoclonal, HumanizedHumansMiddle AgedFemaleMaleAgedProspective StudiesCarboplatinAdultTreatment OutcomeAlbumins

Stichwörter der Autor:innen

anti-programmed death-1 (PD-1)camrelizumabesophageal squamous cell carcinoma (ESCC)neoadjuvant therapy

Substanzen

camrelizumabPaclitaxelAntibodies, Monoclonal, HumanizedCarboplatin130-nm albumin-bound paclitaxelAlbumins

Autor:innen und Institutionen

  • Department of Thoracic Surgery, People's Hospital of Yangzhong, China.

Zitieren

APA

Wang, J., Zhang, J., Gao, J., Zhao, M., & Ma, Z. (2023). Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/170265

Vancouver

Wang J, Zhang J, Gao J, Zhao M, Ma Z. Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/170265

BibTeX
@article{Wang2023,
  author = {Wang, Jianping and Zhang, Jian and Gao, Jie and Zhao, Mengmeng and Ma, Zhenkai},
  title = {Neoadjuvant camrelizumab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, open-label study},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2023},
  doi = {10.17219/acem/170265}
}
Kostenlos starten →